Revenue by quarter
US$ · last 8| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $185.6M | -$18.4M | -0.31 |
| Q1 FY2026 | $150.6M | -$19.8M | -0.34 |
| Q4 FY2025 | $143.1M | -$133.7M | -2.32 |
| Q3 FY2025 | $133.5M | -$16.2M | -0.28 |
Newest filings
All 285| Form | Filed | |
|---|---|---|
| 8-K | 3 Aug 2026 | |
| 10-Q | 29 Jul 2026 | |
| 8-K | 29 Jul 2026 | |
| 8-K | 3 Jun 2026 | |
| SD | 29 May 2026 | |
| 8-K | 4 May 2026 | |
| 10-Q | 30 Apr 2026 | |
| 8-K | 29 Apr 2026 |
Description
- Ticker
- GKOS-US
- Exchange
- NYSE
- Index
- S&P SmallCap 600
- Industry
- Surgical & Medical Instruments & Apparatus
- SIC division
- Manufacturing
- CIK
- 0001192448
- LEI
- 5299004JA1LHE21M6T14
- FIGI
- BBG000WG2LQ1
- Share class FIGI
- BBG001T91NX8
- Fiscal year ends
- Dec
- Filings held
- 285 since 2002
- 8-K events
- 144
- Shares short
- 3.9M, 30 Sep 2026
Financial statements
The income statement, balance sheet and cash flow by year and by quarter, line by line as the company reports them. Each column names the filing it comes from.
| Fiscal period | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Filed | 15 Mar 2016 | 15 Mar 2017 | 28 Feb 2018 | 28 Feb 2019 | 2 Mar 2020 | 1 Mar 2021 | 28 Feb 2022 | 24 Feb 2023 | 23 Feb 2024 | 25 Feb 2025 | 23 Feb 2026 | 23 Feb 2026 | 23 Feb 2026 |
| +Net sales | 21M | 46M | 72M | 114M | 159M | 181M | 237M | 225M | 294M | 283M | 315M | 384M | 507M |
| −Cost of sales | 2.5M | 11M | 13M | 16M | 21M | 25M | 39M | 92M | 67M | 69M | 76M | 94M | 112M |
| −Impairment of intangible asset | – | – | – | – | – | – | – | – | – | – | – | – | 113M |
| Gross profit | 18M | 34M | 59M | 98M | 138M | 156M | 198M | 133M | 227M | 214M | 239M | 290M | 283M |
| % of net sales | 87.9% | 75.0% | 81.9% | 85.9% | 86.8% | 86.2% | 83.7% | 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 55.7% |
| +Selling, general and administrative | 17M | 28M | 44M | 65M | 96M | 120M | 177M | 171M | 179M | 193M | 224M | 261M | 332M |
| +Research and development | 16M | 19M | 25M | 29M | 39M | 50M | 68M | 85M | 101M | 123M | 139M | 136M | 151M |
| +Acquired in-process research and development | – | – | – | – | 5.3M | – | 3.7M | – | 10M | 10M | 5M | 14M | – |
| Litigation-related settlement | – | – | – | – | – | – | – | – | 30M | 30M | – | – | – |
| −Total operating expenses | 33M | 47M | 69M | 94M | 141M | 169M | 249M | 257M | 260M | 296M | 368M | 412M | 482M |
| Loss from operations | -14M | -13M | -10M | 4.2M | -2.3M | -13M | -50M | -124M | -33M | -82M | -129M | -122M | -200M |
| +Interest income | 0M | 0M | 0.1M | 0.9M | 1.4Mr | 2.3M | 3.2M | 2.4M | 1.3M | 2.4M | 9.2M | 11M | 11M |
| −Interest expense | – | – | – | – | – | – | 2.6M | 14M | 13M | 14M | 14M | 10M | 4.6M |
| −Charges associated with convertible senior notes | – | – | – | – | – | – | – | – | – | – | – | 18M | – |
| +Other income, net | 0.3M | 0.9M | 1.1M | -0.6M | 0.9M | -1.6M | 0.3M | -3M | 4.3M | 4.8M | -0.6M | -6.3M | 0.5M |
| Total non-operating income | -0M | -0.9M | -28M | 0.3M | 2.3M | 0.6M | 0.3M | -8.8M | -16M | -16M | -5M | -23M | 6.6M |
| Loss before taxes | -14M | -14M | -38M | 4.6M | 0M | -12M | -50M | -132M | -49M | -98M | -134M | -146M | -193M |
| % of net sales | -67.9% | -30.8% | -53.4% | 4.0% | 0.0% | -6.8% | -21.1% | -58.8% | -16.8% | -34.8% | -42.5% | -38.0% | -38.0% |
| −Income tax provision | 0M | 0M | 0M | 0M | 0.1M | 0.6M | -66M | -12M | 0.3M | 0.8M | 0.9M | 0.8M | -5.4M |
| Net income | -14M | -14M | -38M | 4.5M | -0.1M | -13M | 15M | -120M | -50M | -99M | -135M | -146M | -188M |
| Net loss | -13M | -12M | -37M | 4.5M | -0.1M | -13M | 15M | -120M | -50M | -99M | -135M | -146M | -188M |
| Basic net loss per share | – | -5.29 | -2.13 | 0.14 | 0.00 | -0.37 | 0.41 | -2.70 | -1.07 | -2.09 | -2.78 | -2.77 | -3.28 |
| Diluted net loss per share | – | -5.29 | -2.13 | 0.12 | 0.00 | -0.37 | 0.37 | -2.70 | -1.07 | -2.09 | -2.78 | -2.77 | -3.28 |
| Weighted average shares outstanding used to compute basic net loss per share | – | 2.3M | 18M | 33M | 34M | 35M | 37M | 45M | 46M | 47M | 48M | 53M | 57M |
| Weighted average shares outstanding used to compute diluted net loss per share | – | 2.3M | 18M | 37M | 34M | 35M | 41M | 45M | 46M | 47M | 48M | 53M | 57M |
Hover a figure for its source.r restated in a later filing– not reported in that period
Lines in the order and wording of the 10-K filed 23 Feb 2026. 277 of 277 subtotals add up to the company's own totals, and the balance sheet balances in 57 of 57 periods. Newest filing read: 29 Jul 2026.
Free for personal research, with credit (Data by Shikshan Nivesh) and a link. API access, bulk files and commercial use need a licence: the data licence.
Charts
Any figure or ratio in the record, by year, by quarter or on a trailing twelve months, as a value or as growth, against a peer if you like. Hover for the figures.
Revenue · quarterly · US$
Latest Jun 2026: $185.61M
Revenue = rev
Method. Each month-end, the trailing-twelve-month diluted EPS known that month (from filings filed by then) at the 10th, 50th and 90th percentile of this stock's own month-end P/E from 2017-11 to 2022-02. Months with the figure at or below zero are left out. A summary of the multiples the stock has traded at, not a value.
Ratios
Every ratio, worked out the same way for every company, by year or on a trailing twelve months. Hover a ratio for its formula.
| Fiscal year ending | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on common equity | – | – | 132.7% | 4.3% | −0.1% | −8.3% | 3.6% | −18.0% | −7.9% | −17.8% | −27.2% | −23.8% | −26.4% |
| Return on assets | – | – | −52.2% | 3.6% | −0.1% | −6.9% | 3.0% | −13.2% | −4.8% | −9.7% | −13.9% | −15.3% | −20.1% |
| Return on capital | – | – | 56.3% | 3.8% | −1.4% | −6.6% | −8.8% | −14.1% | −3.0% | −7.7% | −13.1% | −12.8% | −27.3% |
| Return on invested capital | – | – | 30.8% | 4.3% | −1.6% | −8.0% | −9.8% | −15.7% | −3.4% | −8.9% | −15.1% | −15.5% | −33.4% |
| Gross margin | 87.9% | 75.0% | 81.9% | 85.9% | 86.8% | 86.2% | 83.7% | 59.2% | 77.3% | 75.6% | 76.0% | 75.5% | 55.7% |
| EBITDA margin | −62.3% | −19.6% | −8.4% | 7.8% | 2.0% | −3.7% | −18.6% | −41.9% | −1.1% | −17.9% | −30.2% | −22.6% | −31.8% |
| Operating margin | −67.8% | −28.9% | −14.4% | 3.7% | −1.4% | −7.2% | −21.2% | −54.9% | −11.2% | −29.1% | −40.9% | −31.9% | −39.3% |
| Incremental operating margin | – | 4.2% | 11.0% | 34.0% | −14.5% | −48.7% | −66.9% | 609.2% | 131.3% | 443.5% | −145.6% | 9.2% | −62.3% |
| Pretax margin | −67.9% | −30.8% | −53.4% | 4.0% | 0.0% | −6.8% | −21.1% | −58.8% | −16.8% | −34.8% | −42.5% | −38.0% | −38.0% |
| Profit margin | −60.3% | −26.6% | −51.9% | 4.0% | −0.1% | −7.1% | 6.5% | −53.5% | −16.9% | −35.1% | −42.8% | −38.2% | −37.0% |
| Net income to common margin | −60.3% | −26.6% | −51.9% | 4.0% | −0.1% | −7.1% | 6.5% | −53.5% | −16.9% | −35.1% | −42.8% | −38.2% | −37.0% |
| Effective tax rate | −0.0% | −0.1% | −0.1% | 0.9% | 9300.0% | −4.7% | 130.8% | 9.0% | −0.7% | −0.8% | −0.7% | −0.5% | 2.8% |
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
Key points
Record quarterly revenue of $185.6 million
Net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis, or 49% on a constant currency basis, compared to $124.1 million in Q2 2025.
Successful global execution drives momentum
Management attributes strong results to successful execution across key commercial and development priorities, positioning the company to sustain growth momentum.
Glaucoma revenue record of $155.2 million
Glaucoma product sales of $155.2 million in Q2 2026 increased 50% year-over-year, representing 84% of total net sales and core business growth.
U.S. Glaucoma accelerating at 64% growth
U.S. Glaucoma sales reached $118.5 million in Q2, growing 64% year-over-year, demonstrating significantly faster domestic market growth than international regions.
GAAP gross margin improved to 82%
Gross margin was approximately 82% in Q2 2026 compared to approximately 78% in the prior year period, reflecting improved manufacturing efficiency and favorable product mix.
Non-GAAP gross margin at 85%
Adjusted for acquisition-related amortization and integration costs, gross margin was approximately 85% compared to 83% in prior year period.
SG&A expenses increased 39% to $116.1 million
Selling, general and administrative expenses grew 39% to $116.1 million from $83.4 million in prior year, reflecting commercial infrastructure investment to support growth.
R&D expenses increased 40% to $51.3 million
Research and development spending grew 40% to $51.3 million from $36.5 million, supporting advancement of pipeline programs including Epioxa and dropless technologies.
GAAP operating loss improved to $17.3 million
Operating loss of $17.3 million in Q2 2026 improved from $22.7 million in prior year, demonstrating operating leverage as revenue growth outpaced expense growth.
Non-GAAP operating loss of $7.6 million
Adjusted operating loss of $7.6 million versus $16.6 million in prior year reflects significant operational improvement when excluding acquisition-related and non-recurring items.
Net loss of $18.4 million or $0.31 per share
Net loss of $18.4 million improved from $19.7 million in prior year period, with loss per diluted share of $0.31 versus $0.34 prior year.
Cash and investments of $289.3 million
At June 30, 2026, the company held $289.3 million in cash, cash equivalents, short-term investments and restricted cash, providing substantial capital for growth.
Zero debt on balance sheet
Company carries no debt, providing full financial flexibility to fund operations, invest in pipeline development, and pursue strategic partnerships or acquisitions.
Two transformational growth drivers
iDose TR, a first-of-its-kind long-duration intracameral procedural pharmaceutical for glaucoma, and Epioxa continue as primary commercial growth drivers.
Guidance
- 2026 full-year net sales$680 million to $700 million2026 · raised from $620 million to $635 million
In their words
“Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa” Thomas Burns, Glaukos chairman and chief executive officer
“We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Coming up
10-Q filing expected by August 10. Company expects to file Form 10-Q for quarter ended June 30, 2026 on or before August 10, 2026.
Continued iDose TR commercialization. Company plans to continue global commercialization of iDose TR with focus on expanding adoption in U.S. and international markets.
Epioxa development and commercialization. Company continues to advance Epioxa as second transformational growth driver with plans to expand commercial efforts.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
- Glaucoma$421.1M 83.0%
- Corneal Health$86.4M 17.0%
- United States$375.0M 73.9%
- International$132.4M 26.1%
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 3 Aug 2026 | 8-K | Investor update | 7.01, 9.01 | |
| 29 Jul 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 3 Jun 2026 | 8-K | Shareholder vote | 5.07 | |
| 4 May 2026 | 8-K | Investor update | 7.01, 9.01 | |
| 29 Apr 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 2 Mar 2026 | 8-K | Investor update | 7.01, 9.01 | |
| 17 Feb 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 13 Jan 2026 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 10 Nov 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 29 Oct 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 12 Aug 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 30 Jul 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 3 Jun 2025 | 8-K | Shareholder vote | 5.07 | |
| 14 May 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 30 Apr 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 12 Mar 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 20 Feb 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 14 Jan 2025 | 8-K | Investor update | 7.01, 9.01 | |
| 9 Dec 2024 | 8-K | Investor update | 7.01 | |
| 3 Dec 2024 | 8-K | Material agreement | 1.01, 9.01 | |
| 15 Nov 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 4 Nov 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 11 Oct 2024 | 8-K | Other events | 8.01, 9.01 | |
| 9 Aug 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 2 Aug 2024 | 8-K/A | Results | 2.02, 9.01 | |
| 31 Jul 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Jun 2024 | 8-K | Share saleOther events | 3.02, 8.01 | |
| 14 Jun 2024 | 8-K | Share saleOther events | 3.02, 8.01, 9.01 | |
| 5 Jun 2024 | 8-K | Leadership changeShareholder vote | 5.02, 5.07, 9.01 | |
| 20 May 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 1 May 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 28 Feb 2024 | 8-K | Investor update | 7.01, 9.01 | |
| 21 Feb 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 9 Jan 2024 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 14 Dec 2023 | 8-K | Investor update | 7.01, 9.01 | |
| 1 Nov 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 18 Aug 2023 | 8-K | Investor update | 7.01, 9.01 | |
| 2 Aug 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 7 Jun 2023 | 8-K | Shareholder vote | 5.07 | |
| 17 May 2023 | 8-K | Investor update | 7.01, 9.01 | |
| 3 May 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 1 Mar 2023 | 8-K | Investor update | 7.01, 9.01 | |
| 22 Feb 2023 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 10 Jan 2023 | 8-K | Investor update | 7.01, 9.01 | |
| 21 Dec 2022 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 | |
| 15 Nov 2022 | 8-K | Investor update | 7.01, 9.01 | |
| 2 Nov 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 7 Sep 2022 | 8-K | Investor update | 7.01, 9.01 | |
| 3 Aug 2022 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | |
| 8 Jun 2022 | 8-K | Shareholder vote | 5.07 |
Every filing
The company's filings with the SEC, newest first: 285 held. Insider, fund and large-holder filings have their own tables below.
| 3 Aug 2026 | 8-K | 3 Aug 2026 | |
| 29 Jul 2026 | 10-Q | 30 Jun 2026 | |
| 29 Jul 2026 | 8-K | 29 Jul 2026 | |
| 3 Jun 2026 | 8-K | 28 May 2026 | |
| 29 May 2026 | SD | – | |
| 4 May 2026 | 8-K | 4 May 2026 | |
| 30 Apr 2026 | 10-Q | 31 Mar 2026 | |
| 29 Apr 2026 | 8-K | 29 Apr 2026 | |
| 16 Apr 2026 | ARS | 31 Dec 2025 | |
| 16 Apr 2026 | DEFA14A | – | |
| 16 Apr 2026 | DEF 14A | 28 May 2026 | |
| 2 Mar 2026 | 8-K | 2 Mar 2026 | |
| 25 Feb 2026 | S-8 | – | |
| 23 Feb 2026 | 10-K | 31 Dec 2025 | |
| 17 Feb 2026 | 8-K | 17 Feb 2026 | |
| 13 Jan 2026 | 8-K | 13 Jan 2026 | |
| 10 Nov 2025 | 8-K | 10 Nov 2025 | |
| 31 Oct 2025 | 10-Q | 30 Sep 2025 | |
| 29 Oct 2025 | 8-K | 29 Oct 2025 | |
| 20 Aug 2025 | S-8 | – | |
| 12 Aug 2025 | 8-K | 12 Aug 2025 | |
| 4 Aug 2025 | 10-Q | 30 Jun 2025 | |
| 30 Jul 2025 | 8-K | 30 Jul 2025 | |
| 3 Jun 2025 | 8-K | 29 May 2025 | |
| 30 May 2025 | SD | – | |
| 14 May 2025 | 8-K | 14 May 2025 | |
| 1 May 2025 | 10-Q | 31 Mar 2025 | |
| 30 Apr 2025 | 8-K | 30 Apr 2025 | |
| 15 Apr 2025 | ARS | 31 Dec 2024 | |
| 15 Apr 2025 | DEFA14A | – | |
| 15 Apr 2025 | DEF 14A | 29 May 2025 | |
| 12 Mar 2025 | 8-K | 12 Mar 2025 | |
| 25 Feb 2025 | 10-K | 31 Dec 2024 | |
| 20 Feb 2025 | 8-K | 20 Feb 2025 | |
| 14 Jan 2025 | 8-K | 14 Jan 2025 | |
| 9 Dec 2024 | 8-K | 9 Dec 2024 | |
| 3 Dec 2024 | 8-K | 2 Dec 2024 | |
| 15 Nov 2024 | 8-K | 15 Nov 2024 | |
| 5 Nov 2024 | 10-Q | 30 Sep 2024 | |
| 4 Nov 2024 | 8-K | 4 Nov 2024 | |
| 11 Oct 2024 | 8-K | 11 Oct 2024 | |
| 9 Aug 2024 | 8-K | 9 Aug 2024 | |
| 2 Aug 2024 | 8-K/A | 31 Jul 2024 | |
| 2 Aug 2024 | 10-Q | 30 Jun 2024 | |
| 31 Jul 2024 | 8-K | 31 Jul 2024 | |
| 28 Jun 2024 | 8-K | 28 Jun 2024 | |
| 14 Jun 2024 | 8-K | 14 Jun 2024 | |
| 5 Jun 2024 | 8-K | 30 May 2024 | |
| 30 May 2024 | SD | – | |
| 20 May 2024 | 8-K | 20 May 2024 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 5 Oct 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 888 | $163.93 | $145.6K | 69,930 | 7 Oct 2026 |
| 5 Oct 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 327 | $164.78 | $53.9K | 69,603 | 7 Oct 2026 |
| 5 Oct 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 312 | $165.60 | $51.7K | 69,291 | 7 Oct 2026 |
| 25 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 167 | $151.70 | $25.3K | 72,266 | 28 Sep 2026 |
| 25 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 136 | $152.71 | $20.8K | 72,130 | 28 Sep 2026 |
| 25 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 229 | $154.24 | $35.3K | 71,901 | 28 Sep 2026 |
| 25 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 1,083 | $154.88 | $167.7K | 70,818 | 28 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 103 | $163.20 | $16.8K | 73,787 | 18 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 345 | $164.60 | $56.8K | 73,442 | 18 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 191 | $166.20 | $31.7K | 73,251 | 18 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 460 | $167.32 | $77.0K | 72,791 | 18 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 120 | $168.38 | $20.2K | 72,671 | 18 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 234 | $170.95 | $40.0K | 72,437 | 18 Sep 2026 |
| 16 Sep 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 4 | $172.00 | $688 | 72,433 | 18 Sep 2026 |
| 28 Aug 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale outside a trading plan | 7,643 | $180.25 | $1.4M | 79,991 | 1 Sep 2026 |
| 28 Aug 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale outside a trading plan | 6,091 | $181.19 | $1.1M | 73,900 | 1 Sep 2026 |
| 28 Aug 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale outside a trading plan | 10 | $182.50 | $1.8K | 73,890 | 1 Sep 2026 |
| 19 Aug 2026 | Kliman Gilbert HDirector | Sale outside a trading plan | 2,500 | $190.00 | $475.0K | 37,406 | 20 Aug 2026 |
| 11 Aug 2026 | Gilliam Joseph EPRESIDENT & COO | Sale outside a trading plan | 27,963 | $178.89 | $5.0M | 104,625 | 13 Aug 2026 |
| 11 Aug 2026 | Gilliam Joseph EPRESIDENT & COO | Sale outside a trading plan | 32,037 | $180.49 | $5.8M | 72,588 | 13 Aug 2026 |
| 7 Aug 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 20,000 | $180.13 | $3.6M | 43,906 | 11 Aug 2026 |
| 31 Jul 2026 | Wen LeanaDirector | Sale outside a trading plan | 525 | $167.63 | $88.0K | 21,092 | 3 Aug 2026 |
| 16 Jul 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 10,000 | $160.00 | $1.6M | 43,906 | 21 Jul 2026 |
| 9 Jul 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 10,000 | $155.00 | $1.6M | 43,681 | 13 Jul 2026 |
| 6 Jul 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 10,000 | $150.00 | $1.5M | 43,681 | 8 Jul 2026 |
| 1 Jul 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 716 | $139.06 | $99.6K | 87,634 | 8 Jul 2026 |
| 16 Jun 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 1,537 | $130.68 | $200.9K | 88,833 | 18 Jun 2026 |
| 14 May 2026 | Kliman Gilbert HDirector | Sale outside a trading plan | 5,000 | $140.76 | $703.8K | 35,528 | 18 May 2026 |
| 11 May 2026 | Kliman Gilbert HDirector | Sale outside a trading plan | 5,000 | $135.00 | $675.0K | 35,528 | 13 May 2026 |
| 1 May 2026 | Gilliam Joseph EPRESIDENT & COO | Sale outside a trading plan | 19,573 | $143.54 | $2.8M | 73,419 | 4 May 2026 |
| 1 May 2026 | Wen LeanaDirector | Sale outside a trading plan | 1,700 | $143.35 | $243.7K | 19,739 | 4 May 2026 |
| 30 Apr 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 10,000 | $140.00 | $1.4M | 43,681 | 4 May 2026 |
| 10 Apr 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 1,237 | $116.72 | $144.4K | 91,226 | 14 Apr 2026 |
| 10 Apr 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 210 | $117.45 | $24.7K | 91,016 | 14 Apr 2026 |
| 10 Apr 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 614 | $119.35 | $73.3K | 90,402 | 14 Apr 2026 |
| 10 Apr 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale under a trading plan | 32 | $120.23 | $3.8K | 90,370 | 14 Apr 2026 |
| 25 Mar 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 2,511 | $106.46 | $267.3K | 41,967 | 27 Mar 2026 |
| 24 Mar 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 1,521 | $105.24 | $160.1K | 46,498 | 25 Mar 2026 |
| 17 Mar 2026 | Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER | Sale under a trading plan | 625 | $99.15 | $62.0K | 49,249 | 19 Mar 2026 |
| 16 Mar 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale outside a trading plan | 460 | $97.33 | $44.8K | 74,202 | 19 Mar 2026 |
| 16 Mar 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale outside a trading plan | 299 | $98.21 | $29.4K | 73,903 | 19 Mar 2026 |
| 16 Mar 2026 | Navratil TomasCHIEF DEVELOPMENT OFFICER | Sale outside a trading plan | 272 | $99.05 | $26.9K | 73,631 | 19 Mar 2026 |
| 19 Feb 2026 | Weisner Aimee SDirector | Sale outside a trading plan | 2,153 | $115.69 | $249.1K | 31,653 | 23 Feb 2026 |
| 19 Feb 2026 | Weisner Aimee SDirector | Sale outside a trading plan | 5,242 | $116.64 | $611.4K | 26,411 | 23 Feb 2026 |
| 19 Feb 2026 | Weisner Aimee SDirector | Sale outside a trading plan | 1,134 | $117.33 | $133.1K | 25,277 | 23 Feb 2026 |
| 19 Feb 2026 | Weisner Aimee SDirector | Sale outside a trading plan | 6,471 | $118.56 | $767.2K | 18,806 | 23 Feb 2026 |
| 22 Jan 2026 | Stapley MarcDirector | Sale under a trading plan | 3,812 | $126.07 | $480.6K | 48,637 | 26 Jan 2026 |
| 22 Jan 2026 | Stapley MarcDirector | Sale under a trading plan | 3,892 | $126.96 | $494.1K | 44,745 | 26 Jan 2026 |
| 22 Jan 2026 | Stapley MarcDirector | Sale under a trading plan | 1,671 | $127.92 | $213.8K | 43,074 | 26 Jan 2026 |
| 22 Jan 2026 | Stapley MarcDirector | Sale under a trading plan | 4,325 | $129.11 | $558.4K | 38,749 | 26 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 5 Oct 2026 | Navratil TomasOfficer | 1,527 | $251.1K | 5 Oct 2026 |
| 25 Sep 2026 | Navratil TomasOfficer | 1,615 | $249.2K | 25 Sep 2026 |
| 16 Sep 2026 | Navratil TomasOfficer | 1,457 | $243.2K | 16 Sep 2026 |
| 28 Aug 2026 | Navratil TomasOfficer | 13,744 | $2.5M | 28 Aug 2026 |
| 19 Aug 2026 | Kliman Gilbert HDirector | 2,500 | $475.0K | 19 Aug 2026 |
| 11 Aug 2026 | Gilliam Joseph EOfficer | 60,000 | $10.8M | 11 Aug 2026 |
| 7 Aug 2026 | Thurman Alex R.Officer | 20,000 | $3.6M | 7 Aug 2026 |
| 31 Jul 2026 | WEN LEANADirector | 525 | $88.0K | 31 Jul 2026 |
| 16 Jul 2026 | Thurman Alex R.Officer | 10,000 | $1.6M | 16 Jul 2026 |
| 9 Jul 2026 | Thurman Alex R.Officer | 10,000 | $1.6M | 9 Jul 2026 |
| 6 Jul 2026 | Thurman Alex R.Officer | 10,000 | $1.5M | 6 Jul 2026 |
| 1 Jul 2026 | Navratil TomasOfficer | 716 | $99.6K | 1 Jul 2026 |
| 16 Jun 2026 | Navratil TomasOfficer | 1,537 | $200.9K | 16 Jun 2026 |
| 14 May 2026 | Kliman Gilbert HDirector | 5,000 | $703.8K | 14 May 2026 |
| 11 May 2026 | Kliman Gilbert HDirector | 5,000 | $675.0K | 11 May 2026 |
| 1 May 2026 | WEN LEANADirector | 1,700 | $247.1K | 1 May 2026 |
| 1 May 2026 | Gilliam Joseph EOfficer | 19,573 | $2.8M | 1 May 2026 |
| 30 Apr 2026 | Thurman Alex R.Officer | 10,000 | $1.4M | 30 Apr 2026 |
| 10 Apr 2026 | Navratil TomasOfficer | 2,093 | $246.2K | 10 Apr 2026 |
| 25 Mar 2026 | Thurman Alex R.Officer | 2,511 | $267.3K | 25 Mar 2026 |
| 24 Mar 2026 | Thurman Alex R.Officer | 1,521 | $160.1K | 24 Mar 2026 |
| 17 Mar 2026 | Thurman Alex R.Officer | 625 | $62.0K | 17 Mar 2026 |
| 16 Mar 2026 | Navratil TomasOfficer | 1,031 | $101.0K | 16 Mar 2026 |
| 19 Feb 2026 | WEISNER AIMEE SDirector | 15,000 | $1.8M | 19 Feb 2026 |
| 22 Jan 2026 | Gilliam Joseph EOfficer | 10,498 | $1.3M | 22 Jan 2026 |
| 22 Jan 2026 | Stapley MarcDirector | 15,000 | $1.9M | 22 Jan 2026 |
| 21 Jan 2026 | Gilliam Joseph EOfficer | 4,502 | $561.2K | 21 Jan 2026 |
| 16 Jan 2026 | Burns Thomas WilliamOfficer, Director | 186,945 | $21.5M | 16 Jan 2026 |
| 8 Jan 2026 | Burns Thomas WilliamOfficer, Director | 88,055 | $10.1M | 8 Jan 2026 |
| 9 Dec 2025 | Kliman Gilbert HDirector | 5,000 | $536.4K | 9 Dec 2025 |
| 25 Nov 2025 | Thurman Alex R.Officer | 315 | $33.1K | 25 Nov 2025 |
| 18 Nov 2025 | Gilliam Joseph EOfficer | 19,340 | $1.7M | 18 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 15 May 2026 | JANUS HENDERSON GROUP PLC | 13G amended | 9.2% | 5.3M |
| 29 Apr 2026 | Vanguard Portfolio Management | 13G | 5.6% | 3.3M |
| 29 Apr 2026 | Vanguard Capital Management | 13G | 5.07% | 2.9M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | JANUS HENDERSON GROUP PLC | 13G | 5.3% | 3.0M |
| 11 Feb 2026 | PRIMECAP MANAGEMENT CO/CA/ | 13G | 5.88% | 3.4M |
| 10 Feb 2026 | Wellington Management Group LLP | 13G amended | 0.85% | 486.8K |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
| 30 Sep 2026 | 3.9M | -7.58% | 4.08 |
| 15 Sep 2026 | 4.2M | +9.02% | 5.71 |
| 31 Aug 2026 | 3.8M | -3.28% | 6.65 |
| 14 Aug 2026 | 4.0M | +8.95% | 5.21 |
| 31 Jul 2026 | 3.6M | -22.9% | 3.64 |
| 15 Jul 2026 | 4.7M | +5.7% | 6.29 |
| 30 Jun 2026 | 4.4M | +6.56% | 4.46 |
| 15 Jun 2026 | 4.2M | +33.9% | 3.49 |
| 29 May 2026 | 3.1M | -5.66% | 2.05 |
| 15 May 2026 | 3.3M | +13.78% | 4.26 |
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
406
quarter to 30 Jun 2026
Added or new
207
since 31 Mar 2026
Trimmed
103
in the quarter
Largest holder
BlackRock, Inc.
$1.3B
| BlackRock, Inc. | $1.3B | 9.5M | +450.0K | Added | 0.02% | Filing ↗ |
| Jupiter Topco LLC | $679.6M | 4.9M | – | first | 0.28% | Filing ↗ |
| Vanguard Portfolio Management LLC | $464.3M | 3.3M | +113.5K | Added | 0.02% | Filing ↗ |
| Primecap Management Co. | $425.0M | 3.0M | -329.9K | Trimmed | 0.25% | Filing ↗ |
| Vanguard Capital Management LLC | $356.5M | 2.6M | +42.4K | Added | 0.01% | Filing ↗ |
| State Street Corp. | $323.7M | 2.3M | +133.0K | Added | 0.01% | Filing ↗ |
| Millennium Management LLC | $221.0M | 1.6M | +407.3K | Added | 0.15% | Filing ↗ |
| Holocene Advisors, LP | $211.7M | 1.5M | +131.2K | Added | 0.48% | Filing ↗ |
| Geode Capital Management, LLC | $204.6M | 1.5M | +107.0K | Added | 0.01% | Filing ↗ |
| Citadel Advisors LLC | $194.3M | 1.4M | -56.9K | Trimmed | 0.11% | Filing ↗ |
| Ameriprise Financial Inc. | $183.8M | 1.3M | -295.7K | Trimmed | 0.04% | Filing ↗ |
| Capital World Investors | $142.0M | 1.0M | +26.9K | Added | 0.02% | Filing ↗ |
| AllianceBernstein L.P. | $135.1M | 1.3M | -142.9K | Trimmed | 0.04% | Filing ↗ |
| Goldman Sachs Group Inc. | $125.4M | 897.0K | -477.9K | Trimmed | 0.01% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $105.2M | 752.6K | +38.3K | Added | 0.01% | Filing ↗ |
| Invesco Ltd. | $98.8M | 706.9K | -207.3K | Trimmed | 0.01% | Filing ↗ |
| Price T Rowe Associates Inc. | $95.0M | 679.6K | +343.2K | Added | 0.01% | Filing ↗ |
| William Blair Investment Management, LLC | $92.5M | 661.7K | -412.1K | Trimmed | 0.28% | Filing ↗ |
| Driehaus Capital Management LLC | $90.9M | 650.6K | +162.7K | Added | 0.53% | Filing ↗ |
| Nomura Asset Management International Inc. | $90.5M | 647.4K | +35.4K | Added | 0.14% | Filing ↗ |
| Northern Trust Corp. | $85.6M | 612.5K | +36.3K | Added | 0.01% | Filing ↗ |
| Braidwell LP | $82.7M | 591.9K | -171.6K | Trimmed | 3.18% | Filing ↗ |
| Morgan Stanley | $82.4M | 589.8K | -89.0K | Trimmed | 0.00% | Filing ↗ |
| Bank of America Corp. | $82.1M | 587.3K | -70.1K | Trimmed | 0.01% | Filing ↗ |
| UBS Group AG | $80.8M | 578.3K | +191.9K | Added | 0.01% | Filing ↗ |
| Fuller & Thaler Asset Management, Inc. | $74.1M | 529.9K | +529.9K | New | 0.20% | Filing ↗ |
| Norges Bank | $69.7M | 498.5K | – | Held | 0.01% | Filing ↗ |
| Balyasny Asset Management L.P. | $68.7M | 491.6K | +491.6K | New | 0.13% | Filing ↗ |
| Jennison Associates LLC | $68.7M | 491.5K | +4.5K | Added | 0.04% | Filing ↗ |
| Westfield Capital Management Co. LP | $67.6M | 483.4K | +1.2K | Added | 0.22% | Filing ↗ |
| Loomis Sayles & Co. L P | $65.6M | 469.4K | +48.1K | Added | 0.08% | Filing ↗ |
| Summit Partners Public Asset Management, LLC | $62.4M | 446.6K | +446.6K | New | 1.62% | Filing ↗ |
| Clearbridge Investments, LLC | $60.2M | 431.1K | +145.0K | Added | 0.05% | Filing ↗ |
| Wellington Management Group LLP | $59.8M | 428.2K | +279.1K | Added | 0.01% | Filing ↗ |
| Lord, Abbett & Co. LLC | $58.8M | 420.5K | +300.3K | Added | 0.18% | Filing ↗ |
| Vanguard Fiduciary Trust Co. | $58.3M | 417.4K | +20.7K | Added | 0.01% | Filing ↗ |
| Vaughan Nelson Investment Management, L.P. | $58.2M | 416.2K | +416.2K | New | 0.51% | Filing ↗ |
| Allspring Global Investments Holdings, LLC | $57.5M | 418.0K | +24.2K | Added | 0.09% | Filing ↗ |
| FMR LLC | $52.8M | 377.5K | +74.2K | Added | 0.00% | Filing ↗ |
| Principal Financial Group Inc. | $50.1M | 358.8K | +78.0K | Added | 0.03% | Filing ↗ |
| Bank of New York Mellon Corp | $49.9M | 357.1K | +14.0K | Added | 0.01% | Filing ↗ |
| Nuveen, LLC | $45.1M | 322.6K | -75.7K | Trimmed | 0.01% | Filing ↗ |
| Marshall Wace, LLP | $44.0M | 314.8K | +280.7K | Added | 0.04% | Filing ↗ |
| Artisan Partners Limited Partnership | $43.2M | 309.3K | -298.2K | Trimmed | 0.07% | Filing ↗ |
| Neuberger Berman Group LLC | $42.0M | 300.8K | +152.9K | Added | 0.03% | Filing ↗ |
| Riverbridge Partners LLC | $39.4M | 282.1K | -151.1K | Trimmed | 1.10% | Filing ↗ |
| Anomaly Capital Management, LP | $38.6M | 276.0K | +276.0K | New | 1.47% | Filing ↗ |
| Champlain Investment Partners, LLC | $38.5M | 275.2K | -43.9K | Trimmed | 0.99% | Filing ↗ |
| Toronto Dominion Bank | $37.5M | 268.2K | +232.0K | Added | 0.06% | Filing ↗ |
| Longaeva Partners L.P. | $33.0M | 236.2K | +236.2K | New | 0.95% | Filing ↗ |
Executive pay and performance
What the chief executive and the other named officers were paid, as reported and as actually paid, next to the shareholder return and net income, from each proxy's pay-versus-performance table.
| Fiscal year | CEO pay, as reported | CEO pay, actually paid | Other officers, as reported (average) | Other officers, actually paid (average) | Shareholder return, $100 | Peer return, $100 | Net income | NetSales | Proxy |
|---|---|---|---|---|---|---|---|---|---|
| FY ending 31 Dec 2025 | $12.0M | $10.0M | $4.7M | $1.4M | $150 | $78 | $-187.7M | $507.4M | DEF 14A 16 Apr 2026 |
| FY ending 31 Dec 2024 | $9.0M | $25.2M | $3.1M | $9.9M | $199 | $78 | $-146.4M | $383.5M | DEF 14A 16 Apr 2026 |
| FY ending 31 Dec 2023 | $8.7M | $22.3M | $3.0M | $7.7M | $106 | $76 | $-134.7M | $314.7M | DEF 14A 16 Apr 2026 |
| FY ending 31 Dec 2022 | $6.3M | $5.5M | $2.9M | $2.4M | $58 | $78 | $-99.2M | $282.9M | DEF 14A 16 Apr 2026 |
| FY ending 31 Dec 2021 | $7.3M | $-0.2M | $2.2M | $0.5M | $59 | $106 | $-49.6M | $294.0M | DEF 14A 16 Apr 2026 |
| FY ending 31 Dec 2020 | $6.0M | $11.8M | $2.2M | $4.8M | $138 | $131 | $-120.3M | $225.0M | DEF 14A 15 Apr 2025 |
Each year from the newest proxy that reports it. Pay actually paid follows the SEC's definition and can be below zero when share awards fall in value. n the proxy's net income differs from the 10-K or was tagged without its scale: hover for which.
Shareholder votes
The vote count on every proposal at each meeting, from the company's 8-K.
| Proposal | For | Against or withheld | Abstain | Broker non-votes | For, % of for and against | Result |
|---|---|---|---|---|---|---|
| Proposal 1. The election of two Class II directors to hold office until the 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified: | ||||||
| Denice M. Torres | 40,843,317 | 11,169,168 | – | 3,024,243 | 78.5% | – |
| Aimee S. Weisner | 49,397,952 | 2,614,533 | – | 3,024,243 | 95.0% | – |
| Proposal 2. The non-binding advisory vote regarding approval of the compensation of the Company’s named executive officers: | ||||||
| All shares voting | 47,653,794 | 4,272,830 | 85,861 | 3,024,243 | 91.8% | – |
| Proposal 3. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026: | ||||||
| All shares voting | 54,476,088 | 515,703 | 44,937 | – | 99.1% | – |
Counts as the company reports them in its 8-K. A result shows when the filing states one. Meetings since 2023.
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Glaukos Corp.this company | $10.5B | $612.8M | 41.5% | -31.6% | -30.7% | -27.6% | – | – |
| Stryker Corp. | $117.8B | $25.8B | 8.5% | 21.4% | 14.4% | 15.5% | 31.8× | 18.1× |
| 3M Co. | $89.6B | $25.2B | 1.7% | 18.8% | 14.0% | 85.7% | 25.9× | 16.2× |
| Boston Scientific Corp. | $66.2B | $21.0B | 13.5% | 19.8% | 17.5% | 14.7% | 18.5× | 14.1× |
| Becton Dickinson & Co. | $54.2B | $20.8B | -2.6% | 9.6% | 4.5% | 3.9% | 59.9× | 15.8× |
| Resmed Inc. | $36.5B | $5.7B | 9.9% | 33.4% | 26.9% | 23.1% | 24.2× | 17.1× |
| Dexcom Inc. | $29.4B | $5.0B | 15.5% | 22.9% | 20.1% | 38.1% | 30.8× | 21.1× |
| West Pharmaceutical Services Inc. | $27.6B | $3.3B | 12.4% | 20.5% | 17.0% | 18.9% | 50.2× | 31.8× |
| Solventum Corp. | $14.5B | $8.3B | -0.9% | 25.0% | 17.3% | 29.9% | 10.4× | 7.5× |
| Baxter International Inc. | $13.1B | $11.5B | 5.4% | -2.4% | -9.3% | -17.1% | – | 30.0× |
| Penumbra Inc. | $12.8B | $1.5B | 17.6% | 12.4% | 10.7% | 10.5% | 79.8× | 61.6× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence